Department of Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730, Beijing, China.
Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
BMC Infect Dis. 2024 Apr 17;24(1):409. doi: 10.1186/s12879-024-09320-1.
Metagenomic next-generation sequencing (mNGS) has been increasingly applied in sepsis. We aimed to evaluate the diagnostic and therapeutic utility of mNGS of paired plasma and peritoneal drainage (PD) fluid samples in comparison to culture-based microbiological tests (CMTs) among critically ill patients with suspected acute intra-abdominal infections (IAIs).
We conducted a prospective study from October 2021 to December 2022 enrolling septic patients with suspected IAIs (n = 111). Pairwise CMTs and mNGS of plasma and PD fluid were sent for pathogen detection. The mNGS group underwent therapeutic regimen adjustment based on mNGS results for better treatment. The microbial community structure, clinical features, antibiotic use and prognoses of the patients were analyzed.
Higher positivity rates were observed with mNGS versus CMTs for both PD fluid (90.0% vs. 48.3%, p < 0.005) and plasma (76.7% vs. 1.6%, p < 0.005). 90% of enrolled patients had clues of suspected pathogens combining mNGS and CMT methods. Gram-negative pathogens consist of most intra-abdominal pathogens, including a great variety of anaerobes represented by Bacteroides and Clostridium. Patients with matched plasma- and PD-mNGS results had higher mortality and sepsis severity. Reduced usage of carbapenem (30.0% vs. 49.4%, p < 0.05) and duration of anti-MRSA treatment (5.1 ± 3.3 vs. 7.0 ± 8.4 days, p < 0.05) was shown in the mNGS group in our study.
Pairwise plasma and PD fluid mNGS improves microbiological diagnosis compared to CMTs for acute IAI. Combining plasma and PD mNGS could predict poor prognosis. mNGS may enable optimize empirical antibiotic use.
宏基因组下一代测序(mNGS)在脓毒症中的应用越来越广泛。我们旨在评估 mNGS 检测配对血浆和腹腔引流(PD)液样本与基于培养的微生物学检测(CMTs)在疑似急性腹腔内感染(IAI)的危重症患者中的诊断和治疗效用。
我们进行了一项前瞻性研究,纳入了 2021 年 10 月至 2022 年 12 月期间疑似 IAI 的脓毒症患者(n=111)。进行了配对的 CMT 和血浆及 PD 液的 mNGS 以检测病原体。mNGS 组根据 mNGS 结果调整治疗方案以获得更好的治疗效果。分析了患者的微生物群落结构、临床特征、抗生素使用和预后。
mNGS 对 PD 液(90.0% vs. 48.3%,p<0.005)和血浆(76.7% vs. 1.6%,p<0.005)的阳性率均高于 CMTs。90%的纳入患者通过 mNGS 和 CMT 联合方法发现了疑似病原体的线索。革兰氏阴性病原体构成了大多数腹腔内病原体,包括各种厌氧菌,代表菌为拟杆菌属和梭菌属。具有匹配的血浆和 PD-mNGS 结果的患者死亡率和脓毒症严重程度更高。在本研究中,mNGS 组中碳青霉烯类药物(30.0% vs. 49.4%,p<0.05)和抗耐甲氧西林金黄色葡萄球菌(MRSA)治疗时间(5.1±3.3 天 vs. 7.0±8.4 天,p<0.05)的使用减少。
与 CMTs 相比,配对的血浆和 PD 液 mNGS 可提高急性 IAI 的微生物学诊断。联合检测血浆和 PD 液 mNGS 可预测不良预后。mNGS 可能有助于优化经验性抗生素使用。